Grapefruit juice interacts with some drugs and causes adverse effects that can be finalized with death. Especially blood pressure regulating, antihistaminic and cholesterol drugs cause this interaction with naringin, naringenin, furanocumarin, bergapten (5-methoxypsoralen), bergomottin and flavonoids of grapefruit juice. This compounds inhibit decomposition of drugs with the related enzymes in intestines and liver. As a result of this, concentration of the drug in blood is increased and poisioning is occured.
Bailey D. G., Dresser G. K., Kreeft J. H., Munoz C., Freeman D. J. and Bend J. R. 2000. Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients. Clinical Pharmacology & Therapeutics. volume: 68, lssue: 5 , 468-477.
Becquemont L, verstuyft c., Kerb R., Bnnkmann U., Lebot M., Jaillon P. and Brentano C. F. 2001. Effect of grapefruit juice on digoxin pharmacokinelics in humans. Clinical Pharmacology & Therapeutics. volume 70, Issue: 4, 311-316.
Cemerogiu B. ye Karadeniz F. 2001. Meyve Suyu Uretim Teknoloyisi, Gida Teknolojisi Dernegi Yayanlari, No: 25, 384 s., Ankara.
Charbit B., Becquemont L., Lepére B., Peytavin G.and Brentano C. F. 2002. Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.CIinlcal Pharmacology & Therapeutics volume: 72, Issue: 5, 514-523.
Ho P.C., Saville D.J., Coville P. F. and Wanwimolruk S. 2000. Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products. Pharmaceutica Acta Helvetiae volume 74, Issue: 4, 379-385.
Kiliç O., BaçogIu F. ve copur O.u. 1997. Meyve ve Sebze lsieme Teknolojisi I, uludag universitesi ziraat Fakultesi Ders Notlari, No: 73. 192 s., Bursa.
Lilja J. J., Kivistö K. T. and Neuvonen P. J. 2000. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clinical Pharmacology & Therapeutics volume 68. Issue: 4. 384-390.
LIIja J.J, Juntti P.L., and Neuvonen P. J. 2004. Orange juice substantially reduces the bioavailabllity of the beta-adrenergic-blocking agent celiprolol. 1: Gun Pharmacol Ther. 75(a):1 84-90.
Pisank P., 1996. Arch Fam Med, clinical Briefs in Primary Care, volume 1; 413-416.
Tassaneeyakul w., Guo L.Q., Fukuda K., Ohta T. and Yama.zoe V. 2000. InhIbition selectivity of grapefruit juice components on human cytochromes P450. Archives of Biochemistry and Biophysics. Volume: 378, Issue: 2 , 356-363.
Schobinger U. 1987. Meyve ve Sebze Suyu 0retim Teknoloyisi. çeviren Jale Acar. Hacettepe Univ. Yayinlani, 602 s., Ankara.
Greyfurt suyu bazı ilaçlarla etkileşime girerek ölümle sonuçlanabilen yan etkiler oluşturmaktadır. Özellikle tansiyon, kolesterol ve antihistaminik ilaçlarla görülen bu etkileşim, greyfurt suyunda bulunan naringin, naringenin, furanokumarin, bergapten (5-methoxypsoralen), bergomottin ve flavonoidler tarafından gerçekleştirilmektedir. Bu maddeler, ilacın, bağırsak ve karaciğerde bulunan ilgili enzimce parçalanmasını önlemekte ve sonuçta ilacın kandaki konsantrasyonunun artışına bağlı olarak ilaç zehirlenmesi meydana gelmektedir.
Bailey D. G., Dresser G. K., Kreeft J. H., Munoz C., Freeman D. J. and Bend J. R. 2000. Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients. Clinical Pharmacology & Therapeutics. volume: 68, lssue: 5 , 468-477.
Becquemont L, verstuyft c., Kerb R., Bnnkmann U., Lebot M., Jaillon P. and Brentano C. F. 2001. Effect of grapefruit juice on digoxin pharmacokinelics in humans. Clinical Pharmacology & Therapeutics. volume 70, Issue: 4, 311-316.
Cemerogiu B. ye Karadeniz F. 2001. Meyve Suyu Uretim Teknoloyisi, Gida Teknolojisi Dernegi Yayanlari, No: 25, 384 s., Ankara.
Charbit B., Becquemont L., Lepére B., Peytavin G.and Brentano C. F. 2002. Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.CIinlcal Pharmacology & Therapeutics volume: 72, Issue: 5, 514-523.
Ho P.C., Saville D.J., Coville P. F. and Wanwimolruk S. 2000. Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products. Pharmaceutica Acta Helvetiae volume 74, Issue: 4, 379-385.
Kiliç O., BaçogIu F. ve copur O.u. 1997. Meyve ve Sebze lsieme Teknolojisi I, uludag universitesi ziraat Fakultesi Ders Notlari, No: 73. 192 s., Bursa.
Lilja J. J., Kivistö K. T. and Neuvonen P. J. 2000. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clinical Pharmacology & Therapeutics volume 68. Issue: 4. 384-390.
LIIja J.J, Juntti P.L., and Neuvonen P. J. 2004. Orange juice substantially reduces the bioavailabllity of the beta-adrenergic-blocking agent celiprolol. 1: Gun Pharmacol Ther. 75(a):1 84-90.
Pisank P., 1996. Arch Fam Med, clinical Briefs in Primary Care, volume 1; 413-416.
Tassaneeyakul w., Guo L.Q., Fukuda K., Ohta T. and Yama.zoe V. 2000. InhIbition selectivity of grapefruit juice components on human cytochromes P450. Archives of Biochemistry and Biophysics. Volume: 378, Issue: 2 , 356-363.
Schobinger U. 1987. Meyve ve Sebze Suyu 0retim Teknoloyisi. çeviren Jale Acar. Hacettepe Univ. Yayinlani, 602 s., Ankara.